B. M. Stoltz et al.
(KAUST). The authors wish to thank NIH-NIGMS (R01M080269-01),
Amgen, Abbott, Boehringer Ingelheim, Merck, and Bristol-Myers
Squibbs, GlaxoSmithKline, Johnson and Johnson, Amgen, Merck Re-
search Laboratories, Pfizer, Novartis, Roche, Abbott Laboratories, Boeh-
ringer-Ingelheim, AstraZeneca, and Caltech for financial support. We
also wish to thank Dr. M. W. Day and Mr. L. M. Henling for X-ray crys-
tallographic expertise, Dr. Andrew Harned, Dr. David White, Daniel
Caspi, and J. T. Mohr for helpful discussions, and Professor Mark T.
Hamann for authentic samples and spectra of cyanthiwigins B, F, and G.
Ruthenium olefin metathesis catalysts were generously donated by Mate-
ria.
erant of a diastereomeric mixture of racemic and meso start-
ing materials in the same catalytic transformation. Because
of the ease with which stereoisomeric mixtures of precursor
bis(b-ketoester) 36 can be prepared, this stereoablative ap-
proach expedites the early phases of our synthesis consider-
ably. Our strategy also involves an efficient, single operation
ring-closing and cross-metathesis reaction to generate a bi-
cyclic aldehyde from a monocyclic tetraolefin. Combined
with a radical cyclization reaction, these techniques furnish
ready and rapid access to a versatile tricyclic intermediate
representing the completed cyathane core (63). By leverag-
ing this core compound as a branching point toward marine
natural products, our group was able to expediently prepare
multiple cyanthiwigin molecules. In particular, the total syn-
thesis of cyanthiwigin F (6) was accomplished in nine total
[1] D. Green, I. Goldberg, Z. Stein, M. Ilan, Y. Kashman, Nat. Prod.
Lett. 1992, 4, 193–199.
[2] a) J. Peng, K. Walsh, V. Weedman, J. D. Bergthold, J. Lynch, K. L.
5, 4575–4578; c) J. Peng, N. Kasanah, C. E. Stanley, J. Chadwick, M.
[3] a) D. L. Wright, C. R. Whitehead, Org. Prep. Proced. Int. 2000, 32,
309–330; b) J. A. Enquist, Jr., Nat. Prod. Rep. 2009, 26, 661–680.
[4] T. Saito, F. Aoki, H. Hirai, T. Inagaki, Y. Matsunaga, T. Sakakibara,
S. Sakemi, Y. Suzuki, S. Watanabe, O. Suga, T. Sujaku, A. A. Smogo-
wicz, S. J. Truesdell, J. W. Wong, A. Nagahisa, Y. Kojima, N. Kojima,
J. Antibiot. 2003, 51, 983–990.
[5] a) Y. Obara, N. Nakahata, T. Kita, Y. Takaya, H. Kobayashi, S.
zumi, N. Nakahata, Mol. Pharmacol. 2001, 59, 1287–1297.
ꢀ
steps, seven of which form carbon carbon bonds. Addition-
ally, the synthesis is highly efficient in terms of its use of
redox reactions, as only minimal oxidative or reductive pro-
cesses are employed. The flexibility and modularity of our
synthetic route later accommodated further extrapolation of
tricyclic intermediate 63 toward additional members of the
cyanthiwigin family, thus facilitating the preparation of cyan-
thiwigins B (2) and G (7).
Experimental Section
15045; b) J. T. Mohr, D. C. Behenna, A. M. Harned, B. M. Stoltz,
For general methods and complete Experimental Section, please see Sup-
porting Information.
Synthesis of diketone 35: A flame dried round bottom flask cooled under
argon was charged with bis(3,5-dimethoxydibenzylideneacetone)palladi-
um(0) ([PdACHTUNGTRENNUNG(dmdba)2], 0.268 g, 0.330 mmol, 0.05 equiv) and (S)-tBuPHOX
(43) (0.140 g, 0.362 mmol, 0.055 equiv). The flask was purged under
vacuum briefly, and then backfilled with argon. The solids were dissolved
in Et2O (500 mL), and the resulting solution was stirred at 258C for
30 min. After precomplexation, neat 36 (2.00 g, 6.59 mmol, 1.00 equiv)
was added to the reaction. The solution was stirred vigorously at 258C
for 10 h (Note: continual stirring is necessary due to the apparent low
[12] J. A. Enquist, Jr., B. M. Stoltz, Nature 2008, 453, 1228–1230.
[13] Conditions for this optimized procedure were adapted from
a
solubility of [PdACHTUNGTRENNUNG(dmdba)2] in Et2O.), after which time the solvent was re-
Dieckmann reaction previously published by our group in Organic
Syntheses. See: J. T. Mohr, M. R. Krout, B. M. Stoltz, Org. Synth.
2009, 86, 194–211.
moved in vacuo. The crude oil was purified over silica gel using 3% ethyl
acetate in hexanes as eluent to afford 35 as a colorless oil (1.07 g, 78%,
4.4:1 d.r., 99% ee): Rf =0.7 (15:85 ethyl acetate/hexane); 1H NMR
(300 MHz, CDCl3): d = 5.68 (dddd, J=18.3, 10.2, 6.9, 6.9 Hz, 2H), 5.17–
5.09 (comp. m, 3H), 5.07–5.04 (m, 1H), 2.82 (d, J=14.7 Hz, 2H), 2.38 (d,
J=15 Hz, 2H), 2.34 (app ddt, J=13.2, 6.9, 1.0 Hz, 2H), 2.09 (app ddt,
J=13.5, 7.8, 0.9 Hz, 2H), 1.10 ppm (s, 6H); 13C NMR (125 MHz, CDCl3):
d = 212.8, 132.4, 120.0, 49.4, 48.4, 43.8, 24.3 ppm; IR (neat film, NaCl): n˜
Welter, A. Dahnz, B. Brunner, S. Streiff, P. Dꢂbon, G. Helmchen,
[16] E. L. Eliel, S. H. Wilen, Stereochemistry of Organic Compounds,
Wiley, New York, 1994, pp. 965–971.
= 3078, 2978, 1712, 1640, 1458, 1378, 1252, 1129, 1101, 998, 921 cmꢀ1
;
HRMS (EI): m/z: calcd for C14H20O2 [M]+: 220.1463, found 220.1466;
[a]2D5 = ꢀ163.1 (c = 0.52, CH2Cl2); chiral GC assay (GTA column):
1008C isothermal method over 90 min. tR = 67.7 min (Major enantiomer,
C2 diastereomer, 81.7%), 74.1 min (minor enantiomer, C2 diastereomer,
0.6%), 77.4 min (meso diastereomer, 17.6%). Achiral GC assay (DB-
Wax column): 1008C isotherm over 2.0 min, ramp 58Cminꢀ1 to 1908C,
then 1908C isotherm for 10.0 min; tR
= 18.5 min (C2 diastereomer,
81.0%), 18.7 min (meso diastereomer, 19.0%).
[19] W. Langenbeck, G. Triem, Z. Phys. Chem. Abt. A 1936, 117, 401–
409.
Acknowledgements
1055–1059; b) V. Rautentrauch, Bull. Soc. Chim. Fr. 1994, 131, 515–
524; c) S. E. Baba, K. Sartor, J. Poulin, H. Kagan, Bull. Soc. Chim.
Fr. 1994, 131, 525–533.
This publication is based on work supported by Award No. KUS-11-006-
02, made by King Abdullah University of Science and Technology
9968
ꢀ 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2011, 17, 9957 – 9969